Tango Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Tango Therapeutics, Inc. (TNGX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $16.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-11
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $16.89M, a 157.11% increase year-over-year.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $10.80M, a 48.82% increase year-over-year.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $6.63M, a 7.70% decline year-over-year.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $6.57M, a 12.84% decline year-over-year.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $26.43M, a 8.54% decline from fiscal 2024.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $28.90M, a 51.46% increase from fiscal 2023.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $19.08M, a 34.08% increase from fiscal 2022.
- Tango Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $14.23M, a 81.67% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.89M 10-Q · filed 2026-08-11 | $27.69M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $10.80M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $26.43M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $6.63M 10-Q · filed 2025-11-04 | $13.20M derived: sum of 2 quarters · filed 2026-08-11 | $20.45M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $6.57M 10-Q · filed 2026-08-11 | $13.82M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $7.25M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $28.90M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $7.18M 10-Q · filed 2025-11-04 | $14.72M derived: sum of 2 quarters · filed 2025-11-04 | $21.43M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $7.54M 10-Q · filed 2025-11-04 | $14.26M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $6.72M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $19.08M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $4.86M 10-Q · filed 2024-11-06 | $9.98M derived: sum of 2 quarters · filed 2024-11-06 | $14.20M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $5.12M 10-Q · filed 2024-11-06 | $9.34M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $4.22M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $14.23M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $3.81M 10-Q · filed 2023-11-08 | $7.24M derived: sum of 2 quarters · filed 2023-11-08 | $10.45M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $3.42M 10-Q · filed 2023-11-08 | $6.63M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $3.21M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $7.83M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $3.43M 10-Q · filed 2022-11-10 | $4.63M derived: sum of 2 quarters · filed 2022-11-10 | $5.58M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.20M 10-Q · filed 2022-11-10 | $2.15M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $950.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $1.76M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $418.00K 10-Q · filed 2021-11-09 | $825.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.23M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $407.00K 10-Q · filed 2021-11-09 | $815.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $408.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |